Sarborg Valuation, Funding & Investors

Iambic is a San Francisco-based therapeutics company employing AI to accelerate drug discovery. Its platform integrates Enchant, a multi-modal transformer for early clinical outcome prediction, and NeuralPLexer for protein-ligand structure forecasting. By embedding physics into AI models, Iambic explores vast chemical spaces to target challenging proteins, optimize therapeutic profiles, and conduct weekly design-make-test cycles through automated labs. The company raised $15 million in seed funding in 2022.

DeepRoute.ai is a Shenzhen-based autonomous driving company that delivers mapless L4 solutions through its DeepRoute Driver series, including Driver 3.0 for point-to-point navigation. The firm partners with Chery Automobile to deploy robotaxis in Wuhu and integrates its technology into commercial vehicles from Dongfeng and FAW. Founded in 2019, DeepRoute.ai has conducted over 15 million kilometers of road testing across China and the US with zero accidents reported. Its stackless approach relies on end-to-end neural networks trained on proprietary data from daily operations in complex urban environments.

Replicant is a conversational AI platform that handles complex customer service calls for enterprises. The system processes natural language, slang, and interruptions to resolve inquiries in sectors like telecom and banking. Replicant integrates with backend systems for actions such as account updates and payment processing. New York-headquartered Replicant deploys its voice agents across contact centers to manage high-volume interactions.

Beyond Limits is a Pasadena, California-headquartered AI provider of hybrid cognitive systems for energy, healthcare, and finance sectors. Founded in 2014 as a NASA JPL spinout, its platform fuses symbolic reasoning with deep learning for anomaly detection in oil refineries and patient diagnostics. Deployed at Chevron facilities and Mayo Clinic, it delivers 30 percent faster root-cause analysis.

SmartCella is a Milan-based biotechnology company advancing cell therapy delivery for cardiac regeneration. Its SmartCella device enables precise intracoronary injection of stem cells, drugs, and RNA therapeutics during procedures. Tested in preclinical models for heart failure and myocardial infarction, it partners with clinics in Italy and the EU. Founded in 2016, SmartCella focuses on interventional cardiology applications.

AMP is a Louisville-based AI technology company revolutionizing recycling with smart sortation systems. Its computer vision and robotics platforms identify and separate materials like plastics, metals, and fibers at material recovery facilities. Deployed in over 20 sites across North America and Europe, AMP's solutions recover up to 30 percent more valuable commodities while cutting labor expenses. The company partners with waste management operators such as Waste Connections and Recology to enhance throughput and sustainability.

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

AISpeech is a Chinese technology company focused on speech recognition, natural language processing, tone analysis, and dialogue management systems. Founded in 2002 and headquartered in Beijing, it supplies embedded voice solutions for consumer electronics, automotive, and smart devices manufactured by global brands.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Ring Therapeutics is a biotechnology company developing Anellovector gene therapies derived from human commensal viruses for redosable and targeted treatments. Backed by Flagship Pioneering and based in Cambridge, Massachusetts, it advances platforms beyond traditional gene replacement for diseases like liver disorders and muscle wasting. Founded in 2022, Ring Therapeutics pioneers viral vectors for immunology and oncology applications.

ExaWizards Inc is engaged in Industrial innovation and solving social issues through service development using AI.

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Alpha Biopharma is a Shanghai-headquartered clinical-stage biopharmaceutical company advancing innovative drugs in oncology, immunology, and metabolic diseases. The firm conducts global trials in partnership with CROs and in-licenses assets from international developers, maintaining R&D facilities in China and the US.

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.